Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06944522 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Study acronym: exPDite-2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 42 to 43v14
  2. Study sites: 40 to 42v13
  3. Study sites: 39 to 40v12
  4. Study sites: 37 to 39v11
  5. Trial sites expanded: 33 → 37 locationsv10
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 29 to 33v9
  2. Study sites: 18 to 29v8
  3. Study sites: 14 to 18v7
  4. Study sites: 10 to 14
    • Eligibility criteria expanded, about 104 words
    v6
  5. Study sites: 7 to 10v5
  6. Study sites revised (7)v4
  7. Start date changed from estimate of May 2025 to Jun 17, 2025
    • Site details revised at 1 of 7 sites
    v3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 7 of 7 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
Trial Details
NCT Number NCT06944522
Lead Sponsor BlueRock Therapeutics
Collaborators: Bayer
Conditions
(from sponsor)		 Parkinsons Disease (PD)
Related terms Parkinson Disease
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov